ArcticZymes receives research grant of US$1.3m

Published: 15-Apr-2011

To develop new enzymes for research and diagnostics


ArcticZymes, the marine enzyme subsidiary of Norwegian firm Biotech Pharmacon has received a grant of NOK7.2m (US$1.3m; £813,000; €920,000) from the Research Council of Norway to develop new enzymes for research and diagnostics.

The total project budget is NOK14.4m over three years.

The project is part of the FUGE programme, which aims to establish a stronger product development platform for new enzymes used in molecular biology.

ArcticZymes develops enzymes used in molecular DNA technologies and diagnostics and is a commercial partner in several marine bioprospecting activities that form a large source and pipeline for new commercial enzymes from the Arctic and Barents Sea marine environment, including with the Sfi MabCent consortium and the MARZymes projects at the University of Tromsø.

The partnership with the University of Tromsø in this project will strengthen the entire product development chain and increase capacity from early stage to final product, the company says.

You may also like